Bictegravir - Gilead Sciences
Alternative Names: Bictegravir controlled release - Gilead Sciences; GS 9883Latest Information Update: 05 Mar 2026
At a glance
- Originator Gilead Sciences
- Class Antiretrovirals; Oxazepines; Pyrazines; Pyridones; Small molecules
- Mechanism of Action HIV integrase inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III HIV-1 infections
- Discontinued HIV infections
Most Recent Events
- 25 Feb 2026 Efficacy and adverse events data from the phase II/III ARTISTRY-1 trial in HIV-1 infections released by Gilead Sciences
- 05 Mar 2024 Efficacy and adverse event data from the phase II/III ARTISTRY-1 trial in HIV-1 infections released by Gilead Sciences
- 03 Mar 2024 Updated efficacy data from the phase II/II ARTISTRY-1 trial in HIV infection presented at the Conference on retroviruses and opportunistic infections (CROI-2024)